Search results for "MELD"

showing 10 items of 18 documents

RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit.

2009

Background and Aim: To evaluate the association of the Risk, Injury, Failure, Loss and End-stage renal failure (RIFLE) score on mortality in patients with decompensated cirrho- sis admitted to intensive care unit (ICU). Methods: A cohort of 412 patients with cirrhosis consecutively admitted to ICU was classified according to the RIFLE score. Multivariable logistic regression analysis was used to evaluate the factors associated with mortality. Liver-specific, Acute Physiology and Chronic Health Evaluation (APACHE) II, Sequential Organ Failure Assessment (SOFA) and RIFLE scores on admission, were compared by receiver-operator characteristic curves. Results: The overall mortality during ICU st…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsRisk AssessmentSensitivity and SpecificitySeverity of Illness Indexlaw.inventionHepatorenal syndromelawPredictive Value of TestsRisk FactorsInternal medicineCause of DeathEpidemiologymedicineHealth Status IndicatorsHumansRifleAPACHERetrospective StudiesHepatologybusiness.industryGastroenterologyAcute kidney injuryReproducibility of ResultsOdds ratioAPACHE cirrhosis intensive care unit MELD renal failure RIFLE SOFA.Acute Kidney InjuryMiddle Agedmedicine.diseasePrognosisIntensive care unitSurgeryIntensive Care UnitsLogistic ModelsROC CurveCohortFemalebusinessKidney disease
researchProduct

Effect of serotonin uptake inhibition by zimelidine on hypothalamic-pituitary-adrenal activity

1983

Plasma ACTH levels after oral ingestion of 2 g metyrapone at 24.00 hours in six healthy subjects were higher after pretreatment with zimelidine (300 mg) in comparison to placebo. Since zimelidine is a relatively selective serotonin reuptake inhibitor its action on hypothalamic-pituitary-adrenal (HPA) activity suggests that serotonin is a potent stimulator of ACTH release. The ratio of cortisol to 11-deoxycortisol was taken as a measure of 11-hydroxylase activity, which indicates biological activity of secreted ACTH. These cortisol/11-deoxycortisol ratios were significantly increased after zimelidine treatment, when compared to placebo. Both the ACTH response and the cortisol/11-deoxycortiso…

AdultMaleHypothalamo-Hypophyseal SystemSerotoninendocrine systemmedicine.medical_specialtySerotonin uptakePyridinesSerotonin reuptake inhibitorPituitary-Adrenal SystemPharmacologyPlaceboPlacebosAdrenocorticotropic HormoneInternal medicinemedicineHumansZimelidinePharmacologyMetyraponeChemistryPhysiological conditionZimeldineBiological TransportBiological activityBrompheniramineEndocrinologySerotonin AntagonistsSerotoninhormones hormone substitutes and hormone antagonistsmedicine.drugPsychopharmacology
researchProduct

Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

2021

International audience; Background & aims: Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness.Methods: In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver …

Blood PlateletsLiver CirrhosisNoninvasive Diagnosismedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]PopulationEsophageal and Gastric VaricesChronic liver diseaseSeverity of Illness IndexGastroenterologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineModel for End-Stage Liver DiseaseEsophageal varicesInternal medicineNonalcoholic fatty liver diseasemedicineHumanseducationBaveno VI CriteriaRetrospective Studieseducation.field_of_studyHepatologybusiness.industryGastroenterologyRetrospective cohort studyPortal Hypertensionmedicine.disease3. Good healthMELDCirrhosis030220 oncology & carcinogenesisElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessBaveno VI Criteria Blood Platelets Cirrhosis Elasticity Imaging Techniques End Stage Liver Disease Esophageal and Gastric Varices Humans Liver Cirrhosis MELD Noninvasive Diagnosis Portal Hypertension Retrospective Studies Severity of Illness Index
researchProduct

Mildronate: An Antiischemic Drug for Neurological Indications

2005

Mildronate (3-(2,2,2-trimethylhydrazinium)propionate; MET-88; meldonium, quaterine) is an antiischemic drug developed at the Latvian Institute of Organic Synthesis. Mildronate was designed to inhibit carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of fatty acid beta-oxidation in ischemic tissues and to block this highly oxygen-consuming process. Mildronate is efficient in the treatment of heart ischemia and its consequences. Extensive evaluation of pharmacological activities of mildronate revealed its beneficial effect on cerebral circulation disorders and central nervous system (CNS) functions. The drug is used in neurological clinics for the trea…

Drugmedia_common.quotation_subjectCentral nervous systemIschemiaStimulationKetone BodiesPharmacologyNitric OxideToxicologyModels BiologicalArticleNitric oxidechemistry.chemical_compoundNeuropharmacologyIschemiamedicineAnimalsHumansReceptormedia_commonPharmacologyMeldoniumbusiness.industryCardiovascular Agentsmedicine.diseaseNeuropsychology and Physiological Psychologymedicine.anatomical_structurechemistryMechanism of actionDrug Evaluationmedicine.symptombusinessmedicine.drugMethylhydrazines
researchProduct

Elektronisk meldingsutveksling- et bidrag til å oppfylle Samhandlingsreformens intensjoner om helhetlige, sømløse, koordinerte og trygge tjenester? :…

2014

Masteroppgave i helse- og sosialinformatikk HSI 500 Universitetet i Agder 2014 Project background: Patient information is exchanged between different governmental levels of health care to provide new health level with correct/adequate information. The information exchanged is important in securing a seamless and continuous care. Purpose/problem: This projects objective is to assess the information quality of electronic messages, in particular if the content received meets the recipient’s need of information to customize patient treatment/care. Selection/method: The project made requests to a coordination manager and interaction coordinators in a region, who communicated the projects request…

Elektroniske meldinger ; informasjonsoverføring ; kvalitet ; Electronic messages ; information transfer ; qualityHSI500VDP::Technology: 500::Information and communication technology: 550
researchProduct

Meldingsovervåkning – en sikkerhet ved sending av elektroniske henvisninger : En kvantitativ studie om ulike faktorers påvirkning på meldingsovervåkn…

2018

Masteroppgave i helse- og sosialinformatikk HSI500 - Universitetet i Agder 2018 Using electronic messages is a necessary tool for healthcare providers to be able to perform their work more efficiently. Regarding this, it is very important to maintain an overview and control of the messages that is transmitted between the participants. In order to ensure that a business has procedures for handling application receipts related to electronic messaging, there is a regulatory requirement for how the business should perform this work, both organizational and technical. The purpose of this study is to gain insight into how doctor’s offices in Agder comply with the requirements imposed by the Norwe…

IS successkrav til meldingsutvekslingapplication receiptmeldingsovervåkninglegekontorHSI500applikasjonskvitteringEHR messagingmessage monitoringElectronic messagingelectronic referralmessage exchangedoctor’s officeelektronisk henvisningVDP::Teknologi: 500::Informasjons- og kommunikasjonsteknologi: 550Elektronisk meldingsutvekslingIS-suksess
researchProduct

Zvaigžņotā Debess: 2007/08, Ziema

2007

Latvijas Zinātnes padome, Latvijas Universitāte

Jezuītu darbība ĶīnāPārnova SN2006gyLīgatnes meteorīts – hipotēzeKrustvārdu mīklaArturs Balklavs-Grīnhofs - biogrāfijaLielā Suņa zvaigžņu blīvumsSāmu rūnu bungas – debess karteErnests GrasbergsLatviešu astronoms Staņislavs Vasiļevskis (1907-1988) – biogrāfijaLZA Astrofizikas laboratorija – 50Saturna pavadonis JapetsJauns Einšteina gredzensArnolds LibertsAstronomija un reliģijaGamma staru uzliesmojuma optiskā pēcblāzmaPiepūšamais planetārijs no NorvēģijasNEAR misijas noslēgumsLU Astronomiskais tornisZvaigžņotā debess 2007./08. gada ziemāGrimmu pasaka par zaķi un ezi – Mēness aptumsumsFizikas pasniedzējs Ilmārs EverssIvars ŠmeldsBārzdiņš JānisMarsa robots MSLAstronomiskās parādības - 2008Mars Sample Return misijaCitplanētu dažādībaEdgars MūkinsPlanētu redzamības kompleksā diagramma 2008CAP2007 konference Atēnās
researchProduct

Linjer i profesjonsveiledningen gjennom 50 år

2021

Anmeldelse av Levende tradisjoner i profesjonsveiledning, av Kaare Skagen. Kolofon forlag, 2020.

LC8-6691bokmeldingbokanmeldelseLevende tradisjoner i profesjonsveiledningSpecial aspects of educationNordisk tidsskrift i veiledningspedagogikk
researchProduct

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombo…

2015

Background: A 24-48-week course of interferon-based therapy poorly tolerated in hepatitis C virus (HCV) cirrhosis patients with thrombocytopenia. Aim of the study was to identify patients at low-risk of liver-related complications over a 12-week course of interferon-based therapy. Methods: We assessed the rate of complications and death during the first 12 weeks of interferon-based therapy in HCV cirrhotics with thrombocytopenia (platelets ≤75×109/L) enrolled in the ENABLE-1 and -2 phase 3 randomised controlled trials. Results: Overall, among 1441 patients, 89 complications (6.9%) and 10 deaths (0.7%) were observed within the first 12 weeks of therapy. At univariate analysis baseline albumi…

Liver CirrhosisMaleCirrhosisHepacivirusmedicine.disease_causeGastroenterologyBenzoatesSeverity of Illness IndexLiver-related complicationchemistry.chemical_compoundModel for End-Stage Liver DiseaseRisk FactorsAlbumin levelHydrazineMultivariate AnalysiAged 80 and overUnivariate analysisGastroenterologyHepatitis CMiddle AgedHydrazinesTreatment OutcomeFemaleHumanAdultmedicine.medical_specialtyLiver CirrhosiHepatitis C virusEltrombopagAlpha interferonAntiviral AgentsBenzoateInternal medicineAlbuminsRibavirinmedicineHumansLiver-related mortalityAgedAntiviral AgentHepaciviruHepatologybusiness.industryAlbuminRisk FactorRibavirinMELD scoreInterferon-alphaHepatitis C Chronicmedicine.diseaseThrombocytopeniaSurgerychemistryPyrazoleMultivariate AnalysisPyrazolesbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Akūta alkohola hepatīta klīniskā norise un iznākumi

2015

Diplomdarba tēma. Akūta alkohola hepatīta klīniskā norise un iznākumi. Ievads. Alkohola hepatīts ir klīnisks sindroms, ko izraisa hroniska alkohola lietošana. Akūts alkohola hepatīts vienmēr attīstās uz jau esoša hroniska alkohola aknu bojājuma fona – taukainās hepatozes, steatohepatīta, fibrozes vai cirozes. Agrīna mirstība no alkohola hepatīta variē pēc slimības smaguma no 20% vieglām formām līdz 30-60% smagām formām. Darba mērķis. Pacientiem ar akūtu alkohola hepatītu noteikt un salīdzināt prognostiskos rādītājus pēc Maddrey un MELD aprēķiniem, kas ļautu prognozēt slimības attīstības tendenci un iznākumu pirmreizēji stacionētiem, atkārtoti stacionētiem un mirušiem pacientiem Latvijā. Mat…

Maddrey aprēķinsAlkohola hepatītsMELD aprēķinsAlcoholic hepatitisMedicīnaMaddrey calculation
researchProduct